A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma

Bioscience Reports
Hong-Ling He, Wan-Xia Yao

Abstract

The network meta-analysis was conducted to compare the short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma (RCC). We initially searched databases for randomized controlled trials (RCTs) on different single-drug targeted therapies in treating RCC. The meta-analysis combined the direct and indirect evidence to calculate the pooled odds ratios (OR) and draw surface under the cumulative ranking curves (SUCRA). A total of 14 eligible RCTs were ultimately selected. The partial response (PR) of Cabozantinib in the treatment of RCC was better than Sunitinib (OR = 2.7, 95%CI = 1.0-7.8), Everolimus (OR = 8.1, 95%CI = 3.1-25.0), and Temsirolimus (OR = 4.8, 95%CI = 1.0-31.0); the overall response rate (ORR) of Cabozantinib was better than Sorafenib, Sunitinib, Everolimus, and Temsirolimus (OR = 5.5, 95%CI = 1.1-27.0; OR = 2.6, 95%CI = 1.1-6.6; OR = 8.3, 95%CI = 3.5-20.0; OR = 5.7, 95%CI = 1.3-28.0 respectively). In addition, as for complete response (CR), PR, stable disease (SD), progressive disease (PD), ORR, and disease control rate (DCR), Cabozantinib had the best short-term efficacy among nine single-drug targeted therapies in the treatment of RCC (CR: 50.3%; PR: 93.6%; SD: 75.1%; PD...Continue Reading

References

Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian J Druker
Jul 9, 2005·Trends in Molecular Medicine·David A Guertin, David M Sabatini
Jan 13, 2006·British Journal of Cancer·E PetroulakisN Sonenberg
Jan 24, 2006·Clinical Genitourinary Cancer·Thomas E Hutson, David I Quinn
Feb 9, 2006·British Journal of Cancer·P H PatelR J Motzer
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
May 24, 2008·Molecular Cell·William G Kaelin, Peter J Ratcliffe
Oct 11, 2008·Nature Reviews. Cancer·Bradly G Wouters, Marianne Koritzinsky
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Dec 4, 2008·Cancer·Arkadiusz Z DudekCezary Szczylik
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Jan 18, 2011·Hematology/oncology Clinics of North America·Nancy Berliner
Feb 1, 2011·European Urology·Giuseppe Di LorenzoCarlo Buonerba
Apr 13, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Camillo PortaRobert J Motzer
Jul 19, 2011·Hematology/oncology Clinics of North America·Toni K Choueiri
Jul 19, 2011·Hematology/oncology Clinics of North America·Lianjie Li, William G Kaelin
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Jun 19, 2012·The Journal of Urology·Esther Udoji, Brian R Herts
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierK Fizazi
May 23, 2013·International Journal of Urology : Official Journal of the Japanese Urological Association·Hideyuki Abe, Takao Kamai
May 24, 2013·Korean journal of urology·Jae Hoon Chung, Seung Wook Lee
Jun 19, 2013·Expert Review of Anticancer Therapy·Han Hsi Wong, Tim Eisen
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerThomas E Hutson
Oct 8, 2013·PloS One·Anna ChaimaniGeorgia Salanti
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E HutsonRobert J Motzer
Jan 1, 2012·American Society of Clinical Oncology Educational Book·Daniel Y C Heng, Toni K Choueiri
Apr 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierDavid Cella
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerJennifer J Knox
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Sep 26, 2015·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN METEOR Investigators
Jan 16, 2016·Future Oncology·Hiral ParekhBrian Rini
Jun 22, 2016·Cancer Chemotherapy and Pharmacology·Jwa Hoon KimJae Lyun Lee
Jul 28, 2016·Drug Design, Development and Therapy·Paolo GrassiGiuseppe Procopio

❮ Previous
Next ❯

Software Mentioned

SUCRA
Review Manager
RevMan
gemtc
Open BUGS
R

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.